JP7269923B2 - 呼吸器疾患治療のためのENaC阻害剤としてのビス(ペンタヒドロキシヘキシル)アミノ置換された2-{[(3-アミノ-ピラジン-2-イル)ホルムアミド]メチル}-1H-1,3-ベンゾジアゾール-3-イウム誘導体 - Google Patents

呼吸器疾患治療のためのENaC阻害剤としてのビス(ペンタヒドロキシヘキシル)アミノ置換された2-{[(3-アミノ-ピラジン-2-イル)ホルムアミド]メチル}-1H-1,3-ベンゾジアゾール-3-イウム誘導体 Download PDF

Info

Publication number
JP7269923B2
JP7269923B2 JP2020521539A JP2020521539A JP7269923B2 JP 7269923 B2 JP7269923 B2 JP 7269923B2 JP 2020521539 A JP2020521539 A JP 2020521539A JP 2020521539 A JP2020521539 A JP 2020521539A JP 7269923 B2 JP7269923 B2 JP 7269923B2
Authority
JP
Japan
Prior art keywords
general formula
mmol
amino
methyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020521539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020537658A (ja
JP2020537658A5 (https=
Inventor
アレクサンダー ヘイ ダンカン
ボーレガード スコフィールド トーマス
ウェント ナオミ
マッカーティー クリーブ
Original Assignee
エンタープライズ セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンタープライズ セラピューティクス リミテッド filed Critical エンタープライズ セラピューティクス リミテッド
Publication of JP2020537658A publication Critical patent/JP2020537658A/ja
Publication of JP2020537658A5 publication Critical patent/JP2020537658A5/ja
Application granted granted Critical
Publication of JP7269923B2 publication Critical patent/JP7269923B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020521539A 2017-10-17 2018-10-17 呼吸器疾患治療のためのENaC阻害剤としてのビス(ペンタヒドロキシヘキシル)アミノ置換された2-{[(3-アミノ-ピラジン-2-イル)ホルムアミド]メチル}-1H-1,3-ベンゾジアゾール-3-イウム誘導体 Active JP7269923B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1717051.5 2017-10-17
GBGB1717051.5A GB201717051D0 (en) 2017-10-17 2017-10-17 Compounds
PCT/GB2018/052983 WO2019077340A1 (en) 2017-10-17 2018-10-17 BIS (PENTAHYDROXYHEXYL) AMINO-SUBSTITUTED 2 - {[(3-AMINO-PYRAZIN-2-YL) FORMAMIDO] METHYL} -1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATMENT OF RESPIRATORY DISEASES

Publications (3)

Publication Number Publication Date
JP2020537658A JP2020537658A (ja) 2020-12-24
JP2020537658A5 JP2020537658A5 (https=) 2021-12-09
JP7269923B2 true JP7269923B2 (ja) 2023-05-09

Family

ID=60419129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020521539A Active JP7269923B2 (ja) 2017-10-17 2018-10-17 呼吸器疾患治療のためのENaC阻害剤としてのビス(ペンタヒドロキシヘキシル)アミノ置換された2-{[(3-アミノ-ピラジン-2-イル)ホルムアミド]メチル}-1H-1,3-ベンゾジアゾール-3-イウム誘導体

Country Status (5)

Country Link
US (1) US11370778B2 (https=)
EP (1) EP3697788B1 (https=)
JP (1) JP7269923B2 (https=)
GB (1) GB201717051D0 (https=)
WO (1) WO2019077340A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
CR20220006A (es) 2019-06-12 2022-06-06 Tmem16A Ltd Compuestos para tratar enfermedad respiratoria
EP4259607A1 (en) 2020-12-11 2023-10-18 Tmem16A Limited Benzimidazole derivatives for treating respiratory disease
US20260034237A1 (en) * 2023-01-11 2026-02-05 Genmab A/S Linkers, drug linkers and conjugates thereof and methods of using the same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
JP2014518268A (ja) 2011-06-27 2014-07-28 パリオン・サイエンシィズ・インコーポレーテッド 3,5−ジアミノ−6−クロロ−n−(n−(4−(4−(2−(ヘキシル(2,3,4,5,6−ペンタヒドロキシヘキシル)アミノ)エトキシ)フェニル)ブチル)カルバミミドイル)ピラジン−2−カルボキサミド
JP2016503027A (ja) 2012-12-17 2016-02-01 パリオン・サイエンシィズ・インコーポレーテッド 3,5−ジアミノ−6−クロロ−n−(n−(4−フェニルブチル)カルバムイミドイル)ピラジン−2−カルボキサミド化合物
JP2016503028A (ja) 2012-12-17 2016-02-01 パリオン・サイエンシィズ・インコーポレーテッド 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体
WO2016113167A1 (en) 2015-01-12 2016-07-21 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
WO2017028926A1 (en) 2015-08-20 2017-02-23 Boehringer Ingelheim International Gmbh Novel annelated benzamides
WO2018096325A1 (en) 2016-11-22 2018-05-31 Enterprise Therapeutics Limited Benzodiazolium compounds as enac inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US7375107B2 (en) 2003-08-18 2008-05-20 Parion Sciences, Inc. Alaphatic pyrazinoylguanidine sodium channel blockers
JP2007502829A (ja) 2003-08-18 2007-02-15 パリオン・サイエンシィズ・インコーポレーテッド 環状ピラジノイルグアニジンナトリウムチャネルブロッカー
AU2004266704B2 (en) 2003-08-18 2012-02-23 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US8288391B2 (en) 2007-04-03 2012-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use as taste modulators
CN101687851B (zh) 2007-05-07 2013-02-27 诺瓦提斯公司 有机化合物
WO2009019506A1 (en) 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
WO2009139948A1 (en) 2008-02-26 2009-11-19 Johnson Michael R Poly aromatic sodium channel blockers
AU2009248179A1 (en) 2008-05-13 2009-11-19 Novartis Ag 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of arway diseases
CA2727196A1 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2013064450A1 (en) 2011-11-02 2013-05-10 Boehringer Ingelheim International Gmbh Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
MX2014014648A (es) 2012-05-29 2015-09-04 Parion Sciences Inc Aminoamidas tipo dendrimero que poseen actividad bloqueadora del canal de sodio para el tratamiento de ojo reseco y otras enfermedades mucosas.
WO2014044849A1 (en) 2012-09-24 2014-03-27 Boehringer Ingelheim International Gmbh Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
WO2014177469A1 (en) 2013-04-30 2014-11-06 Boehringer Ingelheim International Gmbh,M Diaminopyrazine compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
US9656972B2 (en) 2013-07-02 2017-05-23 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
JP6449870B2 (ja) 2013-07-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物
EP3022198B1 (en) 2013-07-15 2019-09-11 Boehringer Ingelheim International GmbH Novel 5-substituted benzimidazolium compounds
EP3022196B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel benzimidazolium compounds
EP3022197B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
JP6449880B2 (ja) 2013-08-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ピラジンアミド化合物
JP6667538B2 (ja) 2015-01-12 2020-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患の治療に有用な置換ベンズイミダゾリウム化合物
US9981954B2 (en) 2015-01-12 2018-05-29 Boehringer Ingelheim International Gmbh 2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors
EP3245202B1 (en) 2015-01-12 2020-03-11 Boehringer Ingelheim International GmbH Tetrasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases
CA2996087A1 (en) 2015-08-20 2017-02-23 Boehringer Ingelheim International Gmbh Annelated phenoxyacetamides
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
JP2014518268A (ja) 2011-06-27 2014-07-28 パリオン・サイエンシィズ・インコーポレーテッド 3,5−ジアミノ−6−クロロ−n−(n−(4−(4−(2−(ヘキシル(2,3,4,5,6−ペンタヒドロキシヘキシル)アミノ)エトキシ)フェニル)ブチル)カルバミミドイル)ピラジン−2−カルボキサミド
JP2016503027A (ja) 2012-12-17 2016-02-01 パリオン・サイエンシィズ・インコーポレーテッド 3,5−ジアミノ−6−クロロ−n−(n−(4−フェニルブチル)カルバムイミドイル)ピラジン−2−カルボキサミド化合物
JP2016503028A (ja) 2012-12-17 2016-02-01 パリオン・サイエンシィズ・インコーポレーテッド 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体
WO2016113167A1 (en) 2015-01-12 2016-07-21 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
WO2017028926A1 (en) 2015-08-20 2017-02-23 Boehringer Ingelheim International Gmbh Novel annelated benzamides
WO2018096325A1 (en) 2016-11-22 2018-05-31 Enterprise Therapeutics Limited Benzodiazolium compounds as enac inhibitors

Also Published As

Publication number Publication date
EP3697788B1 (en) 2021-12-15
EP3697788A1 (en) 2020-08-26
WO2019077340A1 (en) 2019-04-25
US11370778B2 (en) 2022-06-28
US20200239442A1 (en) 2020-07-30
JP2020537658A (ja) 2020-12-24
GB201717051D0 (en) 2017-11-29

Similar Documents

Publication Publication Date Title
JP6980014B2 (ja) ENaC阻害剤としてのベンゾジアゾリウム化合物
JP7333793B2 (ja) 化合物
JP7269923B2 (ja) 呼吸器疾患治療のためのENaC阻害剤としてのビス(ペンタヒドロキシヘキシル)アミノ置換された2-{[(3-アミノ-ピラジン-2-イル)ホルムアミド]メチル}-1H-1,3-ベンゾジアゾール-3-イウム誘導体
WO2021014168A1 (en) Solid forms of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-n-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide
US12281077B2 (en) Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide
US12545658B2 (en) Pyridine derivatives as calcium-activated chloride channel modulators
WO2021014169A1 (en) Crystalline form of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-n-cyclohexyl-pyridine-2-carboxamide
HK40068903A (en) Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide
HK40075169A (en) Pyridine derivatives as calcium-activated chloride channel modulators
BR112019009864B1 (pt) Compostos de benzodiazolínio, composição farmacêutica e produto compreendendo os referidos compostos, seus processos de fabricação e uso

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211015

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230424

R150 Certificate of patent or registration of utility model

Ref document number: 7269923

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150